Alzheimer's Disease Drug Development


Book Description

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.




Alzheimer's Disease


Book Description

Nearly 44 million people have Alzheimer's or related dementia worldwide, according to the Alzheimer's Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer's and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer's disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer's disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer's diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer's disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer's disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. - Reviews recent developments of cognitive and clinical studies - Covers factors underlying the transition from mild cognitive impairment to Alzheimer's disease - Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease - Provides a comparison of the effectiveness of various types of treatments




Reducing the Impact of Dementia in America


Book Description

As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.




Preventing Cognitive Decline and Dementia


Book Description

Societies around the world are concerned about dementia and the other forms of cognitive impairment that affect many older adults. We now know that brain changes typically begin years before people show symptoms, which suggests a window of opportunity to prevent or delay the onset of these conditions. Emerging evidence that the prevalence of dementia is declining in high-income countries offers hope that public health interventions will be effective in preventing or delaying cognitive impairments. Until recently, the research and clinical communities have focused primarily on understanding and treating these conditions after they have developed. Thus, the evidence base on how to prevent or delay these conditions has been limited at best, despite the many claims of success made in popular media and advertising. Today, however, a growing body of prevention research is emerging. Preventing Cognitive Decline and Dementia: A Way Forward assesses the current state of knowledge on interventions to prevent cognitive decline and dementia, and informs future research in this area. This report provides recommendations of appropriate content for inclusion in public health messages from the National Institute on Aging.




Brain Longevity


Book Description

In the tradition of Andrew Weil's bestseller Spontaneous Healing, this is a physician's breakthrough medical program for the brain designed to diminish the effect of memory impairment caused by stress, aging, and Alzheimer's disease. As we grow older and experience the stresses of life, at about age 40 many of us begin to have trouble remembering things, concentrating, and generally staying mentally sharp. This book contains a four-part program including nutritional, stress-relieving, pharmacological, and mind-body exercise therapies to help people overcome the undesirable effects of normal brain "aging". By controlling cortisol, a hormone that is toxic to the brain and present in excessive levels as we age, Dr. Khalsa's plan can help improve memory and emotional zest. This is the first book to: Describe a program that may diminish age-associated memory impairment Feature a clinical method that can promote memory functioning impaired by Alzheimer's disease Detail the physical damage done to the brain by stress, how it adversely affects memory and our other mental abilities, and what can be done about it.




Alzheimer's Disease Decoded: The History, Present, And Future Of Alzheimer's Disease And Dementia


Book Description

The book aims to present, educate and inform individuals about Alzheimer's disease in a comprehensive manner. Its scope ranges from the discovery of the disease, epidemiology and basic biological principles underlying it, to advanced stem cell therapies used in the treatment of Alzheimer's. It adopts a 'global' perspective on Alzheimer's disease, and include epidemiological data and science from countries around the world.Alzheimer's disease is a rapidly growing problem seen in every country around the world. This is the first and only comprehensive book to cover Alzheimer's disease, and includes the most updated literature and scientific progress in the field of dementia and Alzheimer's disease research.Most books on the market that focus on Alzheimer's disease are targeted at caregivers as practical advice on how to deal with loved ones with the disease. This book instead is a comprehensive and popular science book that can be read by anyone with an interest in learning more about the disease.Dr. Jefferson Chen MD, PhD, co-author, participated in the world's first surgical clinical trial using shunts to treat Alzheimer's disease. His first-hand involvement in a clinical trial for patients with Alzheimer's disease and experience treating Normal Pressure Hydrocephalus (NPH) which is commonly misdiagnosed as Alzheimer's disease lends a unique perspective.This book with appeal to a wide audience, regardless of their scientific or educational background.




Mayo Clinic on Alzheimer's Disease


Book Description

Annotation This 13-volume set from the Mayo Clinic gives detailed information on various health conditions, for example, high blood pressure, depression, and prostate health. Each book contains a wealth of information including charts and graphs.




A Tattoo on my Brain


Book Description

Dr Daniel Gibbs is one of 50 million people worldwide with an Alzheimer's disease diagnosis. Unlike most patients with Alzheimer's, however, Dr Gibbs worked as a neurologist for twenty-five years, caring for patients with the very disease now affecting him. Also unusual is that Dr Gibbs had begun to suspect he had Alzheimer's several years before any official diagnosis could be made. Forewarned by genetic testing showing he carried alleles that increased the risk of developing the disease, he noticed symptoms of mild cognitive impairment long before any tests would have alerted him. In this highly personal account, Dr Gibbs documents the effect his diagnosis has had on his life and explains his advocacy for improving early recognition of Alzheimer's. Weaving clinical knowledge from decades caring for dementia patients with his personal experience of the disease, this is an optimistic tale of one man's journey with early-stage Alzheimer's disease. Soon to be a documentary film on MTV/Paramount +.




Mayo Clinic on Alzheimer's Disease and Other Dementias


Book Description

A reference on preventing, treating, and coping with dementia, from “one of the most reliable, respected health resources that Americans have” (Publishers Weekly). This book from the world-renowned Mayo Clinic offers an update on what experts know about Alzheimer’s and related dementias, including the latest research into treatment and prevention, ways to live well with dementia, and recommendations for caregivers. While Alzheimer’s disease is the most common type of dementia, many related types also affect adults worldwide, causing loss of memory, reason, judgment, and other cognitive functions. Although the diseases that cause dementia have long been considered unrelenting and incurable, recent advances offer hope. This book includes information about: • What to expect of typical aging and what are the earliest signs of abnormal aging • Memory loss and other forms of cognitive impairment that may lead to dementia • Characteristic features of Alzheimer’s disease and related dementias, including frontotemporal degeneration, Lewy body dementia, and vascular cognitive impairment • The latest research on Alzheimer’s disease and related dementias • Caring for and supporting someone living with dementia Are there ways you can lower your risk? Can dementia be prevented? Can you live well with dementia? If so, how? You’ll find answers to these important questions and more in this book.




The Fragile Brain


Book Description

In Fragile Brains Kathleen Taylor looks at the genetic and lifestyle factors currently linked to the development of dementia, focusing on important new research on how the immune system operates in the brain.